Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (21-30 of 146) with videos related to

Pageof 15
Sort By:
Advances in Therapy|July 11, 2024
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese PatientsAkito Hata, Shunichiro Iwasawa, Yusuke Sasaki, et al.
JTO Clinical and Research Reports|September 30, 2021
Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With <i>MET</i> Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case ReportTaira Ninomaru, Hideaki Okada, Mika Fujishima, et al.
Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry|January 15, 2011
Optimization of peptide density on microarray surface for quantitative phosphoproteomicsTakashi Shimomura, Xiaoming Han, Akito Hata, et al.
Clinical Lung Cancer|September 13, 2018
Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L)Akito Hata, Nobuyuki Katakami, Mototsugu Shimokawa, et al.
Thoracic Cancer|January 21, 2021
Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIsTaira Ninomaru, Akito Hata, Chiyuki Kokan, et al.
Thoracic Cancer|April 16, 2024
Continuous immunotherapy beyond progression in clinical practice for small cell lung cancerKen Yamamoto, Taira Ninomaru, Hideaki Okada, et al.
In Vivo (Athens, Greece)|April 26, 2017
Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy ProceduresAkito Hata, Nobuyuki Katakami, Shigeki Nanjo, et al.
Journal of Gastrointestinal Cancer|December 6, 2012
Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancerAkito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Biomedical Reports|July 8, 2017
Single nucleotide variant sequencing errors in whole exome sequencing using the Ion Proton SystemShiro Fujita, Katsuhiro Masago, Chiyuki Okuda, et al.
Cancer Chemotherapy and Pharmacology|April 30, 2015
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIsTakahisa Kawamura, Akito Hata, Jumpei Takeshita, et al.
Pageof 15

Showing results (21-30 of 146) with videos related to

Sort By:
Pageof 15
Advances in Therapy|July 11, 2024
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese PatientsAkito Hata, Shunichiro Iwasawa, Yusuke Sasaki, et al.
JTO Clinical and Research Reports|September 30, 2021
Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With <i>MET</i> Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case ReportTaira Ninomaru, Hideaki Okada, Mika Fujishima, et al.
Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry|January 15, 2011
Optimization of peptide density on microarray surface for quantitative phosphoproteomicsTakashi Shimomura, Xiaoming Han, Akito Hata, et al.
Clinical Lung Cancer|September 13, 2018
Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L)Akito Hata, Nobuyuki Katakami, Mototsugu Shimokawa, et al.
Thoracic Cancer|January 21, 2021
Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIsTaira Ninomaru, Akito Hata, Chiyuki Kokan, et al.
Thoracic Cancer|April 16, 2024
Continuous immunotherapy beyond progression in clinical practice for small cell lung cancerKen Yamamoto, Taira Ninomaru, Hideaki Okada, et al.
In Vivo (Athens, Greece)|April 26, 2017
Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy ProceduresAkito Hata, Nobuyuki Katakami, Shigeki Nanjo, et al.
Journal of Gastrointestinal Cancer|December 6, 2012
Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancerAkito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Biomedical Reports|July 8, 2017
Single nucleotide variant sequencing errors in whole exome sequencing using the Ion Proton SystemShiro Fujita, Katsuhiro Masago, Chiyuki Okuda, et al.
Cancer Chemotherapy and Pharmacology|April 30, 2015
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIsTakahisa Kawamura, Akito Hata, Jumpei Takeshita, et al.
Pageof 15